NCT04873258View on ClinicalTrials.gov

Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

RecruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

September 27, 2019

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
HealthyFatty LiverMASLDMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseObesity and Obesity-related Medical Conditions
Interventions
DIAGNOSTIC_TEST

Bioimpedence Vector Analysis

Bioimpedence vector analysis

Trial Locations (1)

SE1 1YR

RECRUITING

Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge, London

All Listed Sponsors
collaborator

Richmond Pharmacology Limited

INDUSTRY

lead

Richmond Research Institute

INDUSTRY